Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism

Abstract Evidence suggests that intranasal application of oxytocin facilitates empathy and modulates its underlying neural processes, which are often impaired in individuals with autism spectrum disorders (ASD). Oxytocin has therefore been considered a promising candidate for the treatment of social...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Annalina V. Mayer, Anne-Kathrin Wermter, Sanna Stroth, Peter Alter, Michael Haberhausen, Thomas Stehr, Frieder M. Paulus, Sören Krach, Inge Kamp-Becker
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/4971c2bf295a4bf5828ae8be053f63e2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4971c2bf295a4bf5828ae8be053f63e2
record_format	dspace
spelling	oai:doaj.org-article:4971c2bf295a4bf5828ae8be053f63e22021-12-02T16:17:17ZRandomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism10.1038/s41598-021-94407-x2045-2322https://doaj.org/article/4971c2bf295a4bf5828ae8be053f63e22021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-94407-xhttps://doaj.org/toc/2045-2322Abstract Evidence suggests that intranasal application of oxytocin facilitates empathy and modulates its underlying neural processes, which are often impaired in individuals with autism spectrum disorders (ASD). Oxytocin has therefore been considered a promising candidate for the treatment of social difficulties in ASD. However, evidence linking oxytocin treatment to social behavior and brain function in ASD is limited and heterogeneous effects might depend on variations in the oxytocin-receptor gene (OXTR). We examined 25 male ASD patients without intellectual disability in a double-blind, cross-over, placebo-controlled fMRI-protocol, in which a single dose of oxytocin or placebo was applied intranasally. Patients performed three experiments in the MRI examining empathy for other’s physical pain, basic emotions, and social pain. All participants were genotyped for the rs53576 single-nucleotide polymorphism of the OXTR. Oxytocin increased bilateral amygdala responsiveness during the physical pain task for both painful and neutral stimuli. Other than that, there were no effects of oxytocin treatment. OXTR genotype did not significantly interact with oxytocin treatment. Our results contribute to the growing body of empirical literature suggesting heterogenous effects of oxytocin administration in ASD. To draw clinically relevant conclusions regarding the usefulness of oxytocin treatment, however, empirical studies need to consider methods of delivery, dose, and moderating individual factors more carefully in larger samples.Annalina V. MayerAnne-Kathrin WermterSanna StrothPeter AlterMichael HaberhausenThomas StehrFrieder M. PaulusSören KrachInge Kamp-BeckerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Annalina V. Mayer Anne-Kathrin Wermter Sanna Stroth Peter Alter Michael Haberhausen Thomas Stehr Frieder M. Paulus Sören Krach Inge Kamp-Becker Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism
description	Abstract Evidence suggests that intranasal application of oxytocin facilitates empathy and modulates its underlying neural processes, which are often impaired in individuals with autism spectrum disorders (ASD). Oxytocin has therefore been considered a promising candidate for the treatment of social difficulties in ASD. However, evidence linking oxytocin treatment to social behavior and brain function in ASD is limited and heterogeneous effects might depend on variations in the oxytocin-receptor gene (OXTR). We examined 25 male ASD patients without intellectual disability in a double-blind, cross-over, placebo-controlled fMRI-protocol, in which a single dose of oxytocin or placebo was applied intranasally. Patients performed three experiments in the MRI examining empathy for other’s physical pain, basic emotions, and social pain. All participants were genotyped for the rs53576 single-nucleotide polymorphism of the OXTR. Oxytocin increased bilateral amygdala responsiveness during the physical pain task for both painful and neutral stimuli. Other than that, there were no effects of oxytocin treatment. OXTR genotype did not significantly interact with oxytocin treatment. Our results contribute to the growing body of empirical literature suggesting heterogenous effects of oxytocin administration in ASD. To draw clinically relevant conclusions regarding the usefulness of oxytocin treatment, however, empirical studies need to consider methods of delivery, dose, and moderating individual factors more carefully in larger samples.
format	article
author	Annalina V. Mayer Anne-Kathrin Wermter Sanna Stroth Peter Alter Michael Haberhausen Thomas Stehr Frieder M. Paulus Sören Krach Inge Kamp-Becker
author_facet	Annalina V. Mayer Anne-Kathrin Wermter Sanna Stroth Peter Alter Michael Haberhausen Thomas Stehr Frieder M. Paulus Sören Krach Inge Kamp-Becker
author_sort	Annalina V. Mayer
title	Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism
title_short	Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism
title_full	Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism
title_fullStr	Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism
title_full_unstemmed	Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism
title_sort	randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/4971c2bf295a4bf5828ae8be053f63e2
work_keys_str_mv	AT annalinavmayer randomizedclinicaltrialshowsnosubstantialmodulationofempathyrelatedneuralactivationbyintranasaloxytocininautism AT annekathrinwermter randomizedclinicaltrialshowsnosubstantialmodulationofempathyrelatedneuralactivationbyintranasaloxytocininautism AT sannastroth randomizedclinicaltrialshowsnosubstantialmodulationofempathyrelatedneuralactivationbyintranasaloxytocininautism AT peteralter randomizedclinicaltrialshowsnosubstantialmodulationofempathyrelatedneuralactivationbyintranasaloxytocininautism AT michaelhaberhausen randomizedclinicaltrialshowsnosubstantialmodulationofempathyrelatedneuralactivationbyintranasaloxytocininautism AT thomasstehr randomizedclinicaltrialshowsnosubstantialmodulationofempathyrelatedneuralactivationbyintranasaloxytocininautism AT friedermpaulus randomizedclinicaltrialshowsnosubstantialmodulationofempathyrelatedneuralactivationbyintranasaloxytocininautism AT sorenkrach randomizedclinicaltrialshowsnosubstantialmodulationofempathyrelatedneuralactivationbyintranasaloxytocininautism AT ingekampbecker randomizedclinicaltrialshowsnosubstantialmodulationofempathyrelatedneuralactivationbyintranasaloxytocininautism
_version_	1718384227745005568

Randomized clinical trial shows no substantial modulation of empathy-related neural activation by intranasal oxytocin in autism

Ejemplares similares